These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
380 related articles for article (PubMed ID: 35341570)
1. Potential therapeutic targets for the treatment of opioid abuse and pain. Kiguchi N; Ko MC Adv Pharmacol; 2022; 93():335-371. PubMed ID: 35341570 [TBL] [Abstract][Full Text] [Related]
2. The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability. Lin AP; Ko MC ACS Chem Neurosci; 2013 Feb; 4(2):214-24. PubMed ID: 23421672 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic potentials of NOP and MOP receptor coactivation for the treatment of pain and opioid abuse. Kiguchi N; Ding H; Ko MC J Neurosci Res; 2022 Jan; 100(1):191-202. PubMed ID: 32255240 [TBL] [Abstract][Full Text] [Related]
4. Effects of NOP-Related Ligands in Nonhuman Primates. Kiguchi N; Ko MC Handb Exp Pharmacol; 2019; 254():323-343. PubMed ID: 30879202 [TBL] [Abstract][Full Text] [Related]
5. A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates. Ding H; Kiguchi N; Yasuda D; Daga PR; Polgar WE; Lu JJ; Czoty PW; Kishioka S; Zaveri NT; Ko MC Sci Transl Med; 2018 Aug; 10(456):. PubMed ID: 30158150 [TBL] [Abstract][Full Text] [Related]
6. Nociceptin Receptor-Related Agonists as Safe and Non-addictive Analgesics. Ding H; Kiguchi N; Dobbins M; Romero-Sandoval EA; Kishioka S; Ko MC Drugs; 2023 Jun; 83(9):771-793. PubMed ID: 37209211 [TBL] [Abstract][Full Text] [Related]
7. A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates. Ding H; Czoty PW; Kiguchi N; Cami-Kobeci G; Sukhtankar DD; Nader MA; Husbands SM; Ko MC Proc Natl Acad Sci U S A; 2016 Sep; 113(37):E5511-8. PubMed ID: 27573832 [TBL] [Abstract][Full Text] [Related]
8. Nociceptin/Orphanin FQ Peptide Receptor-Related Ligands as Novel Analgesics. Kiguchi N; Ding H; Kishioka S; Ko MC Curr Top Med Chem; 2020; 20(31):2878-2888. PubMed ID: 32384033 [TBL] [Abstract][Full Text] [Related]
9. Central N/OFQ-NOP Receptor System in Pain Modulation. Kiguchi N; Ding H; Ko MC Adv Pharmacol; 2016; 75():217-43. PubMed ID: 26920014 [TBL] [Abstract][Full Text] [Related]
10. [Therapeutic potentials of safe opioid analgesics targeting nociceptin/orphanin FQ peptide receptor]. Kiguchi N; Kishioka S; Ko MC Nihon Yakurigaku Zasshi; 2021; 156(3):139-144. PubMed ID: 33952840 [TBL] [Abstract][Full Text] [Related]
11. BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates. Kiguchi N; Ding H; Cami-Kobeci G; Sukhtankar DD; Czoty PW; DeLoid HB; Hsu FC; Toll L; Husbands SM; Ko MC Br J Anaesth; 2019 Jun; 122(6):e146-e156. PubMed ID: 30916003 [TBL] [Abstract][Full Text] [Related]
12. Replacement of current opioid drugs focusing on MOR-related strategies. Busserolles J; Lolignier S; Kerckhove N; Bertin C; Authier N; Eschalier A Pharmacol Ther; 2020 Jun; 210():107519. PubMed ID: 32165137 [TBL] [Abstract][Full Text] [Related]
13. Translational value of non-human primates in opioid research. Ding H; Ko MC Exp Neurol; 2021 Apr; 338():113602. PubMed ID: 33453211 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications. Toll L; Khroyan TV; Polgar WE; Jiang F; Olsen C; Zaveri NT J Pharmacol Exp Ther; 2009 Dec; 331(3):954-64. PubMed ID: 19773529 [TBL] [Abstract][Full Text] [Related]